CoChat

Alzheimer’s Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769)

Ferguson, Amy C., Tank, Rachana, Lyall, Laura M., Ward, Joey, Celis-Morales, Carlos, Strawbridge, Rona, Ho, Frederick, Whelan, Christopher D., Gill, Jason, Welsh, Paul, Anderson, Jana J., Mark, Patrick B., Mackay, Daniel F., Smith, Daniel J., Pell, Jill P., Cavanagh, Jonathan, Sattar, Naveed, Lyall, Donald M. · 2020 · Journal of Alzheimer's Disease

Published version of a preprint

Cited by 25

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative condition where the underlying etiology is still unclear. Investigating the potential influence of apolipoprotein E (APOE), a major genetic risk factor, on common blood biomarkers could provide a greater understanding of the mechanisms of AD and dementia risk. OBJECTIVE: Our objective was to conduct the largest (to date) single-protocol investigation of blood biomarkers in the context of APOE genotype, in UK Biobank. METHODS: After quality control and exclusions, data on 395,769 participants of White European ancestry were available for analysis. Linear regressions were used to test potential associations between APOE genotypes and biomarkers. RESULTS: Several biomarkers significantly associated with APOEɛ4 'risk' and ɛ2 'protective' genotypes (versus neutral ɛ3/ɛ3). Most associations supported previous data: for example, ɛ4 genotype was associated with elevated low-density lipoprotein cholesterol (LDL) (standardized beta [b] = 0.150 standard deviations [SDs] per allele, p < 0.001) and ɛ2 with lower LDL (b = -0.456 SDs, p < 0.001). There were however instances of associations found in unexpected directions: e.g., ɛ4 and increased insulin-like growth factor (IGF-1) (b = 0.017, p < 0.001) where lower levels have been previously suggested as an AD risk factor. CONCLUSION: These findings highlight biomarker differences in non-demented people at genetic risk for dementia. The evidence herein supports previous hypotheses of involvement from cardiometabolic and neuroinflammatory pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-200338

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 35

  1. Kimoto, 2016, Serum insulin-like growth factor-I and amyloid beta protein in Alzheimer’s disease: Relationship with cognitive function, Psychogeriatrics, 16, 247, 10.1111/psyg.12149 · DOI
  2. Szalkai, 2017, Identifying combinatorial biomarkers by association rule mining in the CAMD Alzheimer’s database, Arch Gerontol Geriatr, 73, 300, 10.1016/j.archger.2017.08.006 · DOI
  3. Tynkkynen, 2018, Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts, Alzheimers Dement, 14, 723, 10.1016/j.jalz.2018.01.003 · DOI · Paper page
  4. Yamazaki, 2016, Apolipoprotein E as a therapeutic target in Alzheimer’s disease: A review of research and clinical evidence, CNS Drugs, 30, 773, 10.1007/s40263-016-0361-4 · DOI · Paper page
  5. Bycroft, 2018, The UK Biobank resource with deep phenotyping and genomic data, Nature, 562, 203, 10.1038/s41586-018-0579-z · DOI · Paper page
  6. 10.1101/660506 · DOI · Paper page
  7. Lyall, 2019, Assessing for interaction between ɛ4, sex, and lifestyle on cognitive abilities, Neurology, 92, e2691, 10.1212/WNL.0000000000007551 · DOI
  8. Wilkinson, 2019, Identifying dementia outcomes in UK Biobank: A validation study of primary care, hospital admissions and mortality data, Eur J Epidemiol, 34, 557, 10.1007/s10654-019-00499-1 · DOI · Paper page
  9. Townsend, 1988, Health and Deprivation: Inequality and the North
  10. Lyall, 2019, The associations between self-reported depression, self-reported chronic inflammatory conditions and cognitive abilities in UK Biobank, Eur Psychiatry, 60, 63, 10.1016/j.eurpsy.2019.05.007 · DOI
  11. Lyall, 2017, Associations between single andmultiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants, Eur Heart J, 38, 577
  12. Weroha, 2012, The insulin-like growth factor system in cancer, Endocrinol Metab Clin North Am, 41, 335, 10.1016/j.ecl.2012.04.014 · DOI · Paper page
  13. Wisdom, 2011, The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis, Neurobiol Aging, 32, 63, 10.1016/j.neurobiolaging.2009.02.003 · DOI · Paper page
  14. Vidal, 2016, Low serum insulin-like growth factor-I predicts cognitive decline in Alzheimer’s disease, J Alzheimers Dis, 52, 641, 10.3233/JAD-151162 · DOI · Paper page
  15. Lee, 2009, Adult hippocampal neurogenesis and related neurotrophic factors, BMB Rep, 42, 239, 10.5483/BMBRep.2009.42.5.239 · DOI · Paper page
  16. Egert, 2012, ApoE genotype: From geographic distribution to function and responsiveness to dietary factors, Proc Nutr Soc, 71, 410, 10.1017/S0029665112000249 · DOI · Paper page
  17. Maddock, 2015, 25-hydroxyvitamin D, APOE ɛ4 genotype and cognitive function: Findings from the 1958 British birth cohort, Eur J Clin Nutr, 69, 505, 10.1038/ejcn.2014.201 · DOI
  18. Wagner, 2018, Evaluation of the concurrent trajectories of cardiometabolic risk factors in the 14 years before dementia, JAMA Psychiatry, 75, 1033, 10.1001/jamapsychiatry.2018.2004 · DOI · Paper page
  19. Li, 2005, Serum cholesterol and risk of Alzheimer disease, Neurology, 65, 1045, 10.1212/01.wnl.0000178989.87072.11 · DOI · Paper page
  20. Reitz, 2010, Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease, Arch Neurol, 67, 1491, 10.1001/archneurol.2010.297 · DOI · Paper page
  21. Karjalainen, 2019, The effect of apolipoprotein E polymorphism on serum metabolome - a population-based 10-year follow-up study, Sci Rep, 9, 458, 10.1038/s41598-018-36450-9 · DOI · Paper page
  22. Tynkkynen, 2016, Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer’s disease: The National Finnish population study (FINRISK), Age (Dordr), 38, 465, 10.1007/s11357-016-9950-x · DOI
  23. Di Angelantonio, 2012, Lipid-related markers and cardiovascular disease prediction, JAMA, 307, 2499
  24. Slot, 2017, Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer’s disease in non-demented elderly, J Alzheimers Dis, 56, 687, 10.3233/JAD-151068 · DOI · Paper page
  25. Kritharides, 2017, Effect of APOE ɛ genotype on lipoprotein(a) and the associated risk of myocardial infarction and aortic valve stenosis, J Clin Endocrinol Metab, 102, 3390, 10.1210/jc.2017-01049 · DOI
  26. Xing, 2013, Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer’s disease, Prog Neurobiol, 111, 53, 10.1016/j.pneurobio.2013.09.006 · DOI
  27. Chu, 2010, Bioavailable testosterone predicts a lower risk of Alzheimer’s disease in older men, J Alzheimers Dis, 21, 1335, 10.3233/JAD-2010-100027 · DOI · Paper page
  28. Panizzon, 2014, Interaction of APOE genotype and testosterone on episodic memory in middle-aged men, Neurobiol Aging, 35, e1, 10.1016/j.neurobiolaging.2013.12.025 · DOI
  29. Heneka, 2015, Neuroinflammation in Alzheimer’s disease, Lancet Neurol, 14, 388, 10.1016/S1474-4422(15)70016-5 · DOI · Paper page
  30. Martiskainen, 2018, Decreased plasma C-reactive protein levels in APOE ɛ4 allele carriers, Ann Clin Transl Neurol, 5, 1229, 10.1002/acn3.639 · DOI
  31. Yavuz, 2008, Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer’s disease, Int Psychogeriatrics, 20, 815, 10.1017/S1041610208006790 · DOI · Paper page
  32. Pike, 2015, An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimer’s disease and neurodegeneration, Chem Biol Interact, 226, 30, 10.1016/j.cbi.2014.12.006 · DOI
  33. Kaur, 2012, Cystatin C in Alzheimer’s disease, Front Mol Neurosci, 5, 79, 10.3389/fnmol.2012.00079 · DOI · Paper page
  34. Sundelöf, 2008, Serum cystatin C and the risk of Alzheimer disease in elderly men, Neurology, 71, 1072, 10.1212/01.wnl.0000326894.40353.93 · DOI · Paper page
  35. Li, 2017, Serum phosphorus levels and risk of incident Dementia, PLoS One, 12, e0171377, 10.1371/journal.pone.0171377 · DOI

Cited by

See all 25

Metadata

Authors
Ferguson, A. C., Tank, R., Lyall, L. M., Ward, J., Celis-Morales, C., Strawbridge, R., Ho, F., Whelan, C. D., Gill, J., Welsh, P., Anderson, J. J., Mark, P. B., Mackay, D. F., Smith, D. J., Pell, J. P., Cavanagh, J., Sattar, N., & Lyall, D. M.
Venue
Journal of Alzheimer's Disease
Published
2020-08-18
Volume
76
Issue
4
Pages
1541-1551
ISSN
  • 1387-2877
  • 1875-8908
Cited by
25
References
16

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer’s Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). https://app.cochat.ai/papers/10.3233/jad-200338
The paper
Ferguson, A. C., Tank, R., Lyall, L. M., Ward, J., Celis-Morales, C., Strawbridge, R., Ho, F., Whelan, C. D., Gill, J., Welsh, P., Anderson, J. J., Mark, P. B., Mackay, D. F., Smith, D. J., Pell, J. P., Cavanagh, J., Sattar, N., & Lyall, D. M. (2020). Alzheimer’s Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-200338

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.